Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Granfeldt Ostgard LS, Medeiros BC, Sengelov H, Norgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A National Population-Based Cohort Study. J Clin Oncol. 2015;33:3641–9.

Article  PubMed  Google Scholar 

Hulegårdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf Å, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90:208–14.

Article  PubMed  Google Scholar 

Winer ES. Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment. Hematol Oncol Clin North Am. 2020;34:449–63.

Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136:61–70.

Article  PubMed  PubMed Central  Google Scholar 

Dohner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults:2022 ELN recommendations from an international expert panel on behalf of ELN. Blood. 2022;140:1345–77.

Article  PubMed  Google Scholar 

Döhner, DiNardo H, Appelbaum CD, Craddock c FR, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169–73.

Article  PubMed  Google Scholar 

Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nat Commun. 2022;13:4622.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E, Gil C, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6:1278–95.

Article  PubMed  PubMed Central  Google Scholar 

Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115:1850–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, et al. Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for Blood and Bone Marrow Transplantation Study. Biol Blood Marrow Transpl. 2018;24:1406–14.

Article  Google Scholar 

Schmaelter A-K, Labopin M, Socié G, Itälä-Remes M, Blaise D, Yakoub-Agha I, et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020;10:26.

Article  PubMed  PubMed Central  Google Scholar 

Nagler A, Ngoya M, Jacques-Emmanuel G, Labopin M, Kröger N, Socié G, et al. Trends in the outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. Bone Marrow Transpl. 2022;57:1788–96.

Article  Google Scholar 

Nagler A, Labopin M, Blaise D, Raiola AM, Corral LL, Bramanti S, et al Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT. J Hematol Oncol. 2023;16:58.

Nagler A, Labopin M, Tischer J, Raiola AM, Kunadt D, Vydra J, et al. Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT. Blood Adv. 2024;8:4223–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnostic, risk-stratification, and management. Am J Hematol. 2023;98:502–26.

Article  PubMed  Google Scholar 

Nagler A, Labopin M, Dholaria B, Ciceri F, Fraccaroli A, Blaise D, et al. Impact of cytogenetic risk on outcomes of non-T-Cell-depleted haploidentical hematopoietic cell transplantation in patients with relapsed or refractory acute myeloid leukemia. Transpl Cell Ther. 2022;28:773.e1–773.e8.

Article  CAS  Google Scholar 

Nagler A, Labopin M, Craddock C, Socié G, Yakoub-Agha I, Gedde-Dahl T, et al. Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European Society of Blood and Marrow Transplantation. Am J Hematol. 2022;97:274–82.

Article  CAS  PubMed  Google Scholar 

Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, et al. Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European Society for Blood and Marrow transplantation. Am J Hematol. 2020;95:1135–41.

Article  CAS  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009; 15: 1628-33.

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.

CAS  Google Scholar 

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE. et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologicstudy of 20 Seattle patients. Am J Med. 1980;69:204–17.

Article  CAS  PubMed  Google Scholar 

Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone marrow Transpl. 2016;51:610–1.

Article  CAS  Google Scholar 

Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2–4.

Article  PubMed  PubMed Central  Google Scholar 

A language and environment for statistical computing. https://www.R-project.org/. R Core Team: R Foundation for Statistical Computing, Vienna, Austria; 2020.

Medeiros BC, Othus M, Fang M, Appelbaum FR, Erba. HPl. Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. Haematologica. 2015;100:331–5.

Article  PubMed  PubMed Central  Google Scholar 

Slovak ML, Kopecky KJ, Cassileth PA, Harrington, et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–83.

Article  CAS  PubMed  Google Scholar 

Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, et al. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma. 2018;59:601–9.

Article  PubMed  Google Scholar 

Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, et al. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017;123:2035–42.

Article  CAS  PubMed  Google Scholar 

Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood. 2007;110:409–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poiani M, Labopin M, Battipaglia G, Beelen DW, Tischer J, Finke J, et al. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: on behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Am J Hematol. 2021;96:40–50.

Article  CAS  PubMed  Google Scholar 

Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, et al. Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia. 2019;33:1944–52.

Article  CAS  PubMed  Google Scholar 

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Med Res Counc Adult Child’s Leuk Working Parties Blood. 1998;92:2322–33.

CAS  Google Scholar 

Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transpl. 2007;13:655–64.

Article  CAS